BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
BD (NYSE: BDX) announced a significant milestone with the placement of its 1,000th BD Rhapsody™ System at Addenbrooke's Hospital of the University of Cambridge. The BD Rhapsody™ System, launched in 2017, is a leading single-cell multiomics analysis platform that has been cited in over 700 peer-reviewed publications.
The system enables researchers to analyze multiomic data from hundreds of thousands of single cells simultaneously, offering DNA, RNA, and protein analysis capabilities. The latest version, released in 2023, features enhanced sample processing and cell capture technology. BD is expanding the platform's capabilities with new launches, including the BD OMICS-One™ WTA Next Assay for early-access customers and the upcoming BD® OMICS-Guard Cryo for sample preservation.
BD (NYSE: BDX) ha annunciato una tappa significativa con la messa in opera del suo 1.000esimo sistema BD Rhapsody™ presso l'Addenbrooke's Hospital dell'Università di Cambridge. Il sistema BD Rhapsody™, lanciato nel 2017, è una piattaforma leader per l'analisi multiomica a livello di singola cellula che è stata citata in oltre 700 pubblicazioni peer-reviewed.
Il sistema permette ai ricercatori di analizzare dati multiomici da centinaia di migliaia di singole cellule in contemporanea, offrendo analisi di DNA, RNA e proteine. L'ultima versione, rilasciata nel 2023, presenta un processamento campioni e una tecnologia di cattura cellulare migliorati. BD sta espandendo le capacità della piattaforma con nuovi lanci, tra cui il BD OMICS-One™ WTA Next Assay per i clienti in early-access e l'imminente BD® OMICS-Guard Cryo per la conservazione dei campioni.
BD (NYSE: BDX) anunció un hito importante con la colocación de su 1.000º sistema BD Rhapsody™ en el Addenbrooke's Hospital de la Universidad de Cambridge. El BD Rhapsody™ System, lanzado en 2017, es una plataforma líder de análisis multiomico a nivel de una sola célula que ha sido citada en más de 700 publicaciones revisadas por pares.
El sistema permite a los investigadores analizar datos multiomicos de cientos de miles de células individuales simultáneamente, ofreciendo análisis de ADN, ARN y proteínas. La última versión, lanzada en 2023, presenta mejoras en el procesamiento de muestras y en la captura de células. BD está ampliando las capacidades de la plataforma con nuevos lanzamientos, incluidas el BD OMICS-One™ WTA Next Assay para clientes de acceso anticipado y el próximo BD® OMICS-Guard Cryo para la preservación de muestras.
BD (NYSE: BDX)는 케임브리지 대학의 Addenbrooke 병원에 BD Rhapsody™ 시스템 1,000번째를 배치하는 중요한 이정표를 발표했습니다. 2017년에 출시된 BD Rhapsody™ 시스템은 단일 세포 다중 오믹스 분석 플랫폼의 선두주자로, 700편이 넘는 동료 평가 논문에 인용되었습니다.
이 시스템은 연구자들이 수십만 개의 단일 세포에서 멀티오믹 데이터를 동시에 분석할 수 있게 하며, DNA, RNA 및 단백질 분석 기능을 제공합니다. 2023년에 출시된 최신 버전은 시료 처리 및 세포 포획 기술을 향상시켰습니다. BD는 최근 개시 고객용 BD OMICS-One™ WTA Next Assay와 샘플 보존용 BD® OMICS-Guard Cryo를 포함한 플랫폼의 기능 확장을 추진하고 있습니다.
BD (NYSE: BDX) a annoncé une étape importante avec le placement de son 1 000e système BD Rhapsody™ à l'hôpital Addenbrooke de l'Université de Cambridge. Le système BD Rhapsody™, lancé en 2017, est une plateforme leader d'analyse multi-omique à l'échelle d'une seule cellule, citée dans plus de 700 publications évaluées par les pairs.
Le système permet aux chercheurs d'analyser des données multiomiques provenant de centaines de milliers de cellules uniques simultanément, offrant des analyses d'ADN, d'ARN et de protéines. La version la plus récente, publiée en 2023, présente une amélioration du traitement des échantillons et de la captures cellulaires. BD élargit les capacités de la plateforme avec de nouveaux lancements, notamment le BD OMICS-One™ WTA Next Assay pour les clients en accès anticipé et le prochain BD® OMICS-Guard Cryo pour la préservation des échantillons.
BD (NYSE: BDX) hat einen bedeutenden Meilenstein erreicht: Die Platzierung seines 1.000. BD Rhapsody™-Systems im Addenbrooke's Hospital der University of Cambridge. Das BD Rhapsody™-System, das 2017 eingeführt wurde, ist eine führende Plattform zur Einzelzell-Multiomics-Analyse, die in über 700 begutachtungten Publikationen zitiert wurde.
Das System ermöglicht es Forschern, Multiomic-Daten aus Hunderttausenden einzelner Zellen gleichzeitig zu analysieren und bietet DNA-, RNA- und Protein-Analysen. Die jüngste Version, 2023 veröffentlicht, verfügt über verbesserte Probenverarbeitung und Zellfangtechnologie. BD erweitert die Plattform-Kapazitäten mit neuen Veröffentlichungen, darunter der BD OMICS-One™ WTA Next Assay für Frühzugangskunden und dem kommenden BD® OMICS-Guard Cryo zur Probenkonservierung.
BD (NYSE: BDX) أعلنت عن خطوة مهمة مع وضع جهازها BD Rhapsody™ System 1,000 في مستشفى Addenbrooke بجامعة كامبريدج. تعد BD Rhapsody™ System، الذي أُطلق في 2017، منصة رائدة لتحليل متعدد-الأوميكس على مستوى خلية مفردة وقد ذُكرت في أكثر من 700 منشوراً مُراجَعاً من الأقران.
تمكّن النظام الباحثين من تحليل بيانات متعددة الأوميكس من مئات الآلاف من الخلايا المفردة في وقت واحد، مع قدرات تحليل DNA وRNA والبروتين. الإصدار الأحدث، الذي صدر في 2023، يتسم بتحسين معالجة العينات وتقنية التقاط الخلايا. تعمل BD على توسيع قدرات المنصة من خلال إصدارات جديدة، بما في ذلك BD OMICS-One™ WTA Next Assay لعملاء الوصول المبكر وBD® OMICS-Guard Cryo القادم لحفظ العينات.
BD（NYSE: BDX） 宣布在剑桥大学附属 Addenbrooke 医院完成其 第1,000套 BD Rhapsody™ 系统 的部署，标志着一个重要里程碑。BD Rhapsody™ 系统于2017年推出，是领先的单细胞多组学分析平台，已在超过 700 篇同行评议论文 中被引用。
该系统使研究人员能够同时分析数十万到数十万级别的单一细胞的多组学数据，具备 DNA、RNA 与蛋白质分析能力。最新版本于2023年发布，在样本处理和细胞捕获技术方面有所提升。BD 正在通过新的产品发布扩展该平台的能力，包括面向早期访问客户的 BD OMICS-One™ WTA Next Assay，以及即将推出的 BD® OMICS-Guard Cryo，用于样本保存。
- System has achieved strong market adoption with 1,000 installations since 2017
- Platform has been cited in over 700 peer-reviewed publications, demonstrating scientific validity
- Company is expanding product capabilities with new assays and features
- System integrates with other BD instruments, creating a comprehensive workflow solution
- None.
Insights
BD's 1,000th Rhapsody System installation demonstrates strong market position in the growing single-cell analysis field, with continuous innovation strengthening their competitive edge.
The placement of the 1,000th BD Rhapsody System represents a significant commercial milestone for BD's position in the competitive single-cell analysis market. Since its 2017 introduction, the system has been cited in over 700 peer-reviewed publications, demonstrating substantial scientific validation and research impact.
The installation at Cambridge's Addenbrooke's Hospital specifically highlights the system's value in translational medicine applications - moving from basic research toward clinical applications in critical care medicine. This use case exemplifies how single-cell technologies are expanding beyond basic research into more clinically-relevant applications, potentially widening BD's addressable market.
BD's strategic position in the single-cell workflow is particularly noteworthy. The company has created an integrated ecosystem connecting their flow cytometry instruments (FACSDiscover S8 Cell Sorter and A8 Cell Analyzer) with the Rhapsody platform, creating technological synergies that increase switching costs for customers and potentially drive multi-instrument sales.
The announced product roadmap shows continued R&D investment with three upcoming innovations: the OMICS-One WTA Next Assay (reducing per-cell analysis costs), OMICS-Guard Cryo for sample preservation, and workflow automation tools. These additions address key pain points in single-cell analysis - cost, sample handling, and throughput - which should strengthen BD's competitive position against rivals like 10x Genomics.
While specific financial projections aren't provided, this milestone indicates BD has successfully established a foothold in the rapidly growing single-cell analysis market, which is projected to expand significantly as these technologies become essential tools in drug discovery, biomarker identification, and personalized medicine applications.
"Our research focuses on understanding the signaling pathways of immune cells and their role in driving inflammation in patients in intensive care," said Dr. Andrew Conway Morris, associate professor of anesthesia, Addenbrooke's Hospital of the University of
Since the BD Rhapsody™ instrument was introduced in 2017, it has been cited in more than 700 publications in peer-reviewed journals. The latest version, which launched in 2023, allows flexible sample processing and cell capture using a gentle, robust microwell-based cartridge technology, and proprietary BD molecular indexing technology. The captured cellular information is used to generate various types of libraries for next-generation sequencing applications, accelerating time to insight. The BD Rhapsody™ System is uniquely positioned in the cell sorting and analysis workflow with flow cytometry instruments, including the BD FACSDiscover™ S8 Cell Sorter and A8 Cell Analyzer.
"This milestone is a reflection of the critical customer need for a single-cell platform that can offer the right balance of high-performing multiomic assays, without compromising data quality, at the most affordable cost per cell," said Ranga Partha, PhD, VP of global marketing and strategic growth areas, BD Biosciences. "The rapid adoption of the BD Rhapsody™ System is a testament to the fast-evolving scientific need for one complete end-to-end portfolio of single-cell multiomics instruments, reagents, assays, and bioinformatic tools that also work seamlessly alongside leading cell sorters and analyzers."
Innovation around the BD Rhapsody™ System and its workflows continues with upcoming launches:
- BD OMICS-One™ WTA Next Assay is now available for early-access customers, enabling researchers to unlock more genetic information from individual cells at a lower cost-per-cell basis
- BD® OMICS-Guard Cryo will be available this year, enabling researchers to preserve samples for extended periods of time, allowing for batching of analysis
- Robust automation is in development to further standardize and speed workflows
The research of Dr. Andrew Conway Morris is funded by the Medical Research Council, LifeArc, and Addenbrooke's Charitable Trust.
The BD Rhapsody™ System will be featured at the following: Booth 447 at the 2025 Annual Meeting of American Society of Human Genetics (October 14-18 in
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media: | Investors: |
Fallon McLoughlin | Adam Reiffe |
Director, Public Relations | VP, Investor Relations |
201.258.0361 | 201.847.6927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-marks-1-000th-bd-rhapsody-system-driving-scientific-breakthroughs-via-single-cell-multiomics-302557914.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
What milestone did BD (NYSE: BDX) achieve with its Rhapsody System in 2025?
How many publications have cited the BD Rhapsody System since its launch?
What new products is BD launching for the Rhapsody System?
What capabilities does the BD Rhapsody System offer researchers?
When was the latest version of the BD Rhapsody System released?
